University of Tennessee West Cancer Center | Strategic Alliance Partners

November 22, 2019

Bradley G. Somer, MD, discusses the importance of taking a proactive approach towards the use of biosimilars in oncology.

November 22, 2019

Lee S. Schwartzberg, MD, FACP, discusses the development and approval process for biosimilars and explains how their availability could drive down out-of-pocket costs for patients.

November 21, 2019

Bradley G. Somer, MD, discusses the education surrounding biosimilars in oncology.

November 20, 2019

Kurt W. Tauer, MD, FACP, discusses encouraging updates across the spectrum of breast cancer subtypes.

November 19, 2019

Gregory Vidal, MD, PhD, discussed the ways in which currently available and investigational agents are being evaluated in the curative and metastatic settings of HER2-positive breast cancer.

November 16, 2019

Bradley G. Somer, MD, discusses the emergence of biosimilars in oncology

November 16, 2019

Kurt W. Tauer, MD, FACP, discusses the potential implications of biosimilars on cancer research funding.

November 15, 2019

Gregory Vidal, MD, PhD, discusses the potential of [fam-] trastuzumab deruxtecan in HER2-positive breast cancer.

November 15, 2019

Bradley G. Somer, MD, associate professor, Department of Hematology and Medical Oncology, University of Tennessee Health Science Center, medical oncologist, senior partner, Executive Cancer Council, and head of strategic expansion/development, West Cancer Center Research Program, West Cancer Center, explains where the hesitancy regarding biosimilar use in oncology.

November 14, 2019

Lee S. Schwartzberg, MD, FACP, explains how biosimilars could lead to increased competition in oncology.

November 12, 2019

Bradley G. Somer, MD, discusses lowering the cost of cancer care with biosimilars.

November 09, 2019

Kurt Tauer, MD, FACP, discusses arguments in favor of and against biosimilars in oncology.

November 07, 2019

Lee S. Schwartzberg, MD, FACP, chief medical officer, OneOncology, chief and professor of medicine, Division of Hematology/Oncology, the University of Tennessee Health Science Center, medical director, West Clinic, and executive director, West Cancer Center, discusses the use of therapeutic biosimilars in breast cancer.

November 04, 2019

Gregory Vidal, MD, PhD, explains how biosimilars could increase access to HER2-targeted therapy.

July 26, 2019

Daniel Vaena, MD, hematologist/medical oncologist and hematologist, West Cancer Center, discusses progress made in the treatment of patients with metastatic prostate cancer.

April 17, 2019

Holger L. Gieschen, MD, assistant professor, University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the toxicities associated with radiation therapy in prostate cancer.

March 27, 2019

Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses optimal combinations for the treatment of patients with metastatic renal cell carcinoma (mRCC) in the frontline setting.

March 15, 2019

Heather Greene, a nurse practitioner at West Cancer Center, discusses the toxicities that are associated with VEGF TKIs and checkpoint inhibitors in metastatic renal cell carcinoma (mRCC).

February 19, 2019

Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses the racial genomics of prostate cancer.

February 19, 2019

Harsha Ranganath, MD, a fellow in the Division of Hematology & Oncology at the University of Tennessee West Cancer Center, discusses treatment considerations in nonmetastatic prostate cancer.